←
Jon Aning444 posts
Jon Aning avatar

Jon Aning

@jonathananing

Consultant Urological Surgeon (BUI). Hon Professor (@BristolUni). Interests include prostate and bladder cancer & innovation. RT≠E

◷ Joined February 2017▧ 13 Photos and videos
TheUrologyFoundation avatar
⟳ Jon Aning retweeted
TheUrologyFoundation@TUF_tweets·Nov 2

The 3rd UR-UK meeting is bringing together the UK uro-oncology research community. As part of Day 2, UR-UK Catalyst provides a dedicated opportunity for early-career researchers to get involved. 🔬 Find out more 👇 medtribe.com/courses/uro-onc… #UroOncology #UrologyResearch

TheUrologyFoundation avatar
⟳ Jon Aning retweeted
TheUrologyFoundation@TUF_tweets·Oct 21

Meet Professor Jonathan Aning, member of our SEC. Jonathan is a Consultant Urological Surgeon and Honorary Professor of Urological Oncology, passionate about advancing research and improving outcomes for patients. Learn more: theurologyfoundation.org/abo…

Post attachment
TheUrologyFoundation avatar
⟳ Jon Aning retweeted
TheUrologyFoundation@TUF_tweets·Oct 7

We want to hear from the urology community! Five years after launching the TUF Trials Unit, we’re asking researchers, urologists, nurses, patients & others to help us evaluate the service, whether you’ve used it or not. ⏱️ 10–15 mins surveymonkey.com/r/JNZBHS7 #UrologyResearch

Mirrors of Medicine avatar
⟳ Jon Aning retweeted
Mirrors of Medicine@mirrorsmed·Apr 8

Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not Enthusiasm euoncology.europeanurology.c… The ALBAN, CREST, and POTOMAC phase 3 trials in BCG-naïve high-risk NMIBC highlight both promise and limitations of adding checkpoint inhibitors to BCG. While optimized BCG alone achieves over 70% three-year event-free survival, PD-1 combinations modestly reduce recurrences but increase toxicity. No survival or progression benefit is yet shown, raising concerns about overtreatment and cost. Future efforts must prioritize patient selection, progression endpoints, and molecular risk stratification currently in practice. #BladderCancer @UroMoschini Maria Carmen Mir @jonathananing Alessandro Volpe @PiedmontHealth @OncoAlert 🚨

Post attachment
Niyati Lobo avatar
⟳ Jon Aning retweeted
Niyati Lobo@niyatilobo·Mar 16

Interested in learning more about our work on variation in contemporary female radical cystectomy care across the UK & Ireland after hearing @LizzyDay3’s presentation at #EAU26? Check out our @urotoday “Beyond the Abstract” where we dive deeper 👇🏽 🔗 in comments

Post attachment
Bristol Rovers avatar
⟳ Jon Aning retweeted
Bristol Rovers@Official_BRFC·Mar 11

Join us on Wednesday 25 March at 6:30pm for a Prostate Cancer Awareness Evening at the Mem. Geoff Twentyman will be hosting a discussion on symptoms, early detection, rehabilitation and recovery, with a panel of medical experts and our campaign ambassador John Green.

Niyati Lobo avatar
⟳ Jon Aning retweeted
Niyati Lobo@niyatilobo·Feb 4

🚨Female radical cystectomy practice in the UK and Ireland is highly variable- from what we counsel, to the organs we preserve & how we provide survivorship care New data from our survey @BJUIjournal 👇🏽👇🏽👇🏽 🔗 doi.org/10.1111/bju.70159

Post attachment
Matt Nielsen, MD avatar
⟳ Jon Aning retweeted
Matt Nielsen, MD@m_e_nielsen·5 Dec 2025

Huge thanks to Helena Burden and John McGrath for the invitation to the Bristol Urological Institute mtg ✅Transformational, inspiring work being led by the 🤩 team in South West England & other colleagues in @NHSEngland ✅ Immaculate vibes in the unit ✅beautiful city ❤️🙏

Post attachmentPost attachmentPost attachmentPost attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Jon Aning retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·5 Nov 2025

Out on The Guardian A new £1.9 million UK study, the Vanguard Path trial, will evaluate the ArteraAI Prostate Biopsy Assay—an artificial intelligence tool designed to aid prostate cancer diagnosis and treatment decisions—across NHS hospitals. Led by the University of Oxford and funded by Prostate Cancer UK, the three-year study will analyze biopsies from over 4,000 men to determine how effectively the AI model, which generates personalized risk scores from digitized biopsy images, predicts treatment benefit. The tool has already demonstrated value in U.S. trials by identifying which men with high-risk prostate cancer benefit from abiraterone and helping guide hormone and radiotherapy use in less aggressive disease. The UK trial will first validate its predictive accuracy using retrospective patient data, then prospectively test its real-world impact at NHS sites in Oxford, Bristol, and Glasgow. Researchers aim to assess whether the tool influences clinicians’ treatment recommendations, shortens decision-making time, and ultimately reduces both under- and overtreatment, paving the way for potential NHS adoption if proven accurate, cost-effective, and clinically beneficial. #ProstateCancer theguardian.com/society/2025… @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur